Purpose: To describe 2 cases of congenital corneal endothelial edema resulting from novel de novo mutations.
C orneal endothelial dystrophies are a subset of bilateral inherited diseases of the cornea that can result in a severe decline in visual acuity. Characterized by diffuse, noninflammatory corneal edema and opacification arising from severe endothelial cell dysfunction, the disorders encompass several subtypes, including congenital hereditary endothelial dystrophy (CHED; MIM #217700), posterior polymorphous corneal dystrophies (PPCD1; MIM #122000, PPCD3; MIM #609141), Fuchs endothelial corneal dystrophy, and X-linked endothelial corneal dystrophy. Despite their clinically unique features, many of the dystrophies still harbor similar histopathologic hallmarks, including structural aberrations in the individual layers of the cornea, degeneration of corneal endothelial cells, anomalous deposition of collagen on the posterior surface of Descemet membrane, and loss of corneal deturgescence. [1] [2] [3] In the current report, we describe 2 cases of congenital corneal edema without a family history of inherited corneal disease or consanguinity, where candidate gene sequencing assisted in making the diagnosis by the identification of novel de novo mutations. We first describe a case of CHED with a de novo variant resulting in a compound heterozygous mutation in the SLC4A11 gene. We further report a case initially presumed to have the clinical hallmarks of CHED, which was subsequently rediagnosed to be a case of PPCD3 following identification of a novel, de novo mutation in the ZEB1 gene. In this current era of human genomics with its promise of personalized patient care, the 2 cases reported here epitomize how genetic testing can complement careful clinical examination, and histopathologic review, for the proper diagnosis, management, and counseling of the patients with congenital corneal endothelial dystrophies.
MATERIALS AND METHODS
The study protocol had the approval of the institutional review board of the University of Texas Southwestern Medical Center and was in compliance with the tenets of the Declaration of Helsinki. All study subjects were recruited at the University of Texas Southwestern Medical Center after informed consent. The subjects underwent a complete eye examination, including slit-lamp biomicroscopy and/or examination under anesthesia by cornea fellowship-trained ophthalmologists (V.V.M., C.B.B., W.B.).
Penetrating keratoplasty (PKP) specimens were fixed in formalin and embedded sections were processed for standard hematoxylin and eosin staining as described previously. 4 Genomic DNA was extracted from leukocytes of peripheral blood using AutoGen FlexiGene by Qiagen (Valencia, CA). Exon coding regions were amplified by polymerase chain reaction (PCR) with flanking primers and subsequently sequenced by Sanger sequencing. Primers for ZEB1 were selected using ExonPrimer and Primer3 (Helmholtz Center Munich, Institute of Human Genetics), 5 whereas previously described primers were used for SLC4A11. 6 
CASE REPORTS
The case A patient was a 15-month-old white toddler who presented to the pediatric ophthalmologist with a chief complaint of limited ambulation. Parents reported that the child "bumped into things" because of poor vision, noting that the onset was gradual and that the condition was worsening. Parents also reported that the child had bilateral cloudy corneas since birth. The family history was absent for eye disease or consanguinity. The patient's ocular history was also remarkable for strabismus. The pediatric ophthalmologist noted mild stromal edema and stromal haze. Clinical diagnosis of CHED was made by a corneal specialist and future keratoplasty was advised. Preoperative visual acuity was 20/80 OD and 20/80 OS as measured by Allen cards. Corneal pachymetry results showed thickened corneas at 800 mm OD and 800 mm OS. Intraocular pressures were deemed normal by tactile digital pressure, and corneal diameters were also noted to be normal. The anterior and posterior segments of the eye were otherwise normal. At the age of 3 years and 4 months, the patient underwent PKP in both eyes over 2 months. Figure 1A shows 2-month status after PKP to the left eye at which point the right eye was operated on. Five days after PKP to the right eye, the patient suffered a rupture of the OD corneal transplant wound after a fall. Examination under anesthesia revealed that the dehiscence involved 270 degrees of the wound with lens and vitreous prolapse. The patient underwent emergent lensectomy, anterior vitrectomy, and repair of dehisced keratoplasty wound. At the most recent follow-up visit (17 months after initial transplant), both corneal grafts were noted to be clear and best-corrected visual acuity was 20/60 in each eye.
Histopathologic analysis of keratoplasty button showed areas of thickening but also focal loss of Bowman layer centrally ( Fig.  1B) , stromal thickening with edema, and sparse endothelial cells with a thin Descemet membrane (Fig. 1C) . The ocular pathologist's report noted "some features of CHED are present; however, Descemet membrane is extremely thin. Only a few endothelial cells remain. Hence, clinical correlation is required." Both parents were examined and had normal corneal slit-lamp examinations. Given the absence of consanguinity and absence of thickening of Descemet membrane, PCR amplification and traditional Sanger sequencing of the coding exons of SLC4A11 were performed on genomic DNA from the proband and parents. The mother was noted to have a pathogenic heterozygous single-nucleotide polymorphism predicted to result in a missense mutation [SNP rs121909392: NM_032034.3:c.2606G.A, p.(Arg869His)]. In addition to the p.(Arg869His) mutation from his mother, the proband showed a novel de novo mutation in the father's SLC4A11 allele ( Fig. 1D ), resulting in a frameshift mutation [NM_032034.3: c.2450del, p.(Pro817Argfs*32)]. Paternity was confirmed by microsatellite loci genotyping using PowerPlex 1.2 System from Promega (Madison, WI).
The case B patient was a Hispanic child who presented with corneal clouding at the age of 3 to a pediatric ophthalmologist. Per history by the mother, the corneas were "hazy since birth." Family history was unremarkable for eye disease and without consanguinity. At 4 years of age, best spectacle-corrected visual acuity was 20/70 in the OD and 20/80 OS. Examination under anesthesia showed evidence of stromal edema and haze with band keratopathy ( Fig.  2A) . Central corneal pachymetry measured 763 mm OD and 734 mm OS using a Corneo-gage Plus ultrasonic pachymeter (Sonomed, Cleveland, OH). Intraocular pressures were 15 mm Hg OD and 18 mm Hg OS. Corneal diameters were normal. No signs of anterior chamber or intraocular inflammation were noted. The anterior and posterior segments of the eye were otherwise normal. Treatment of band keratopathy was done by a pediatric ophthalmologist at the time of the examination under anesthesia. A clinical diagnosis of CHED was made and PKP was advised upon referral to a corneal specialist. At the age of 4, the patient underwent bilateral PKP-with 3 months separation between procedures. At 8 years and 3 months of age, on the most recent follow-up visit, the patient's visual acuity was 20/25 in each eye and both corneal grafts were noted to be clear.
The preliminary report by a general pathologist remarked on the keratoplasty button findings (Figs. 2B-D) as "consistent with an endothelial dystrophy." The patient's parents and siblings were examined, and all were noted to have normal corneal slit-lamp examinations. PCR amplification and traditional Sanger sequencing of the coding sequence of SLC4A11 revealed no pathogenic variants in proband, siblings, or parents. Sanger sequencing of the exons of the ZEB1 gene was performed in the proband, siblings, and parents. A novel de novo ZEB1 mutation was found in the proband [NM_001174093.1:c.21T.A, p.(Cys7*)] ( Fig. 2E ), which was absent in both parents and siblings. Paternity was confirmed genetically. This single-nucleotide substitution is predicted to result in a nonsense mutation and a premature stop codon. The pathology slides were subsequently reviewed with an ocular pathologist (R.N. H.). Light microscopy analysis of the excised left cornea showed a spongy epithelium with minimal basal epithelium (Fig. 2B ). Discontinuities in Bowman layer were noted. The stroma was thickened, but areas of the posterior stroma were compacted. Descemet membrane displayed regional thinning and thickening and abnormal endothelium (Fig. 2C) . The ocular pathologist noted that the focal multilayered endothelium was consistent with PPCD ( Fig. 2D ).
DISCUSSION
The presented cases illustrate the importance of genetic testing in conjunction with meticulous clinical examination and histopathologic review for the diagnosis, management, and counseling of patients with congenital corneal edema. Additionally, these cases highlight that de novo mutations should be considered in the etiology of congenital corneal endothelial dystrophies in the absence of a family history of corneal disease or presence of consanguinity.
Manifesting at birth or early childhood, CHED (MIM #217700) distinguishes itself by its histological hallmarks, which include dystrophic endothelial cells, a typically thickened Descemet membrane, and diffuse stromal edema that give a distinct "ground glass" appearance to the corneas. The affected gene for CHED has been identified as SLC4A11. 7 The protein product from the SLC4A11 transcript was originally described as a sodium borate cotransporter 1 (NaBC1). 8 More recent work investigating the role of the protein specifically in bovine corneal endothelial cells suggests that the protein does not have any significant affinity for borate and instead seems to function as a sodiumdependent intracellular pH modulator transporting mainly hydroxyl anions. 9 Additional observations from exogenous expression and knockout of SLC4A11 in multiple experimental animal models and human corneas suggest that the protein may also promote basolateral entry of water molecules into corneal endothelium. 10 These observations provide a mechanistic basis for the loss of deturgescence and progressive disorganization of the endothelial layer seen in CHED. Numerous homozygous or compound heterozygous SLC4A11 mutations have been described in CHED individuals. 1, [11] [12] [13] [14] To our knowledge, de novo mutations in SLC4A11 have not been previously described in the literature before this report.
Patient A had clinical features of CHED, but the pathology showed marked loss of endothelium without a thickened Descemet membrane precluding a definitive diagnosis. Additionally, as an autosomal recessive disorder, CHED occurs primarily in patients with a history of consanguinity. Sanger sequencing of the subject and his parents helped make the diagnosis of CHED by the detection of a novel de novo mutation in the paternal SLC4A11 allele combining with a maternal missense mutation p.(Arg869His) to result in a compound heterozygous mutation in the gene. The maternally inherited missense mutation has been previously implicated in CHED and is specifically thought to interrupt the interaction between a specific domain (the transmembrane surface of helix 12) of the cotransporter encoded by SLC4A11 transcript and the cytoplasmic membrane. 6 Interestingly, recent detailed light and electron microscopic studies of Descemet membrane of CHED cases have revealed that marked thickening of this layer is not a universal finding of the disorder. 15, 16 Moreover, a majority of the reported homozygous mutations in exon 18 were associated with only moderate, if any, thickening of Descemet membrane. 15, 16 Although case B also had presented with clinical features of CHED, the pathologic findings and detection of a de novo mutation in ZEB1 helped establish the diagnosis of PPCD3. In contrast to CHED, corneal changes in PPCD usually occur in the second or third decade of life. PPCD also features a more expansive array of clinical manifestations encompassing grouped vesicles, scalloped bands, geographic lesions, and opacities. 2, 3 Although band keratopathy may be a rare association with PPCD, 17 it is a landmark finding of late X-linked endothelial dystrophy presenting in the form of endothelial changes resembling "moon craters." 18 Mutations in ZEB1 (a zinc finger transcription factor) (MIM #609141) are found in nearly one third of all PPCD probands. 2, 3 De novo mutations in ZEB1 have been described in several families. 3, 19 By modulating genes responsible both for maintenance of the epithelial phenotype and the epithelial-to-mesenchymal transition, ZEB1 has been shown to regulate neurodevelopment and tumor metastasis. 1, 20 Interestingly, the case B patient was only 3 years old but presented all the hallmarks of PPCD3, including corneal edema and an abnormal multilayered endothelial cell layer. To our knowledge, our study is the first to report such an early-onset PPCD3 from a de novo mutation. Familial PPCD3 cases of congenital onset 15 and early onset at 3 months of age 21 have been reported previously.
In this era of genomics and promise of personalized medicine, these cases highlight the important role that gene sequencing may play in the diagnosis of congenital corneal endothelial dystrophies with atypical clinical and/or histopathologic presentations. Genetic counseling at the appropriate age is warranted for the case B patient, with the de novo heterozygous mutation in ZEB1, is at risk of passing on the deleterious allele to half of his offspring. Meticulous correlation of mutations to clinicopathologic findings may improve our clinical understanding of these endothelial disorders and also shed light on their underlying molecular biology.
